Pipeline
A robust and nimble engine
We are leveraging our fundamental expertise in immunology and tumor biology to innovate and discover robust and safe TCRs directed against oncogenic and viral driver mutations.
| Programs | Approach | Target | Discovery | Preclinical | Clinical |
|---|---|---|---|---|---|
| Oncogenic Driver Programs | |||||
| AFNT-111 | Lentiviral | KRAS G12V |
|
||
| AFNT-211 | THRIVE™ + FAS-41BB | KRAS G12V |
|
||
| AFNT-212 | THRIVE™ + TUNE™ | KRAS G12D |
|
||
| THRIVE™ + TUNE™ | KRAS G12C |
|
|||
| THRIVE™ + TUNE™ | P53 R175H |
|
|||
| THRIVE™ + TUNE™ | PIK3CA |
|
|||
| Viral Antigen Driver Programs | |||||
| THRIVE™ + TUNE™ | Undisclosed |
|
|||